Wczytywanie spółki
Keep exploring
The themes Nexalin Technology is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Devices
Graded A or B and worth $2B or more: A first, then the largest.
MDTMedtronic plc131,6B USDA+
SYKStryker Corp.117,9B USDA+
EWEdwards Lifesciences Corporation61,6B USDA+
GEHCGE Healthcare Technologies Inc.37,5B USDA
GKOSGlaukos Corp14,5B USDA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 paź 2026CBGraded C, now B
MCKMckesson Corporation4 lis 2026BAGraded B, now A
CVSCVS Health Corp4 lis 2026BAGraded B, now A- EWEdwards Lifesciences Corporation4 lis 2026BAGraded B, now A
- GEHCGE Healthcare Technologies Inc.28 paź 2026CAGraded C, now A
Jak zarabia
- Device sales45%
- Equipment and replacement parts30%
- Licensing fees16%
Udziały w przychodach to szacunki za year ended 2025-12-31, a nie dane z raportu złożonego do regulatora.
Konkuruje z
- Fisher Wallace Laboratories
- Flow Neuroscience
Co sprzedaje5
Gen-1
An earlier cranial electrotherapy stimulation device used by medical professionals. Nexalin continues to service previously sold or leased devices but has paused new United States sales and marketing.
Gen-2 SYNC
A clinical-use device that delivers Nexalin’s newer 15-milliamp electrical waveform. It is under United States regulatory review and clinical development.
Gen-3 HALO
A headset being studied for physician-supervised treatment at home. A United States clinical trial for insomnia is underway.
Pokaż 2 więcej
Nexalin NeuroCare
Software for remote patient monitoring, doctors’ clinical workflows, collection of clinical data and virtual care.
Electrodes and patient cables
Replacement treatment components sold to medical providers using Nexalin devices.
Kto to kupuje2
- Medical professionals and clinics that use Nexalin devices with patients; licensing arrangements generally involve monthly fees, and some charge by the number of treatments.
- International distributors and customers that buy devices and related supplies; Nexalin recorded no international revenue in the six months ended 2026-06-30.
Na czym się opiera i co może to zburzyć
Od czego zależy ta działalność
- 1United States sales of new devices depend on Food and Drug Administration (FDA) clearance or approval; Nexalin’s HALO insomnia study and other clinical and regulatory work are part of that process.
- 2Device assembly, testing and quality checks rely mainly on third-party manufacturers.
- 3Clinical studies rely on outside research organizations and study sites to carry out trials and recruit participants.
- 4China distribution and future device registrations depend in part on Wider, which is responsible for pursuing approvals there.
Co może pójść nie tak
- 1If clinical studies fail, take longer than planned or do not support regulatory applications, Nexalin may not obtain authorization to sell newer devices for the intended uses.
- 2Nexalin has limited revenue, recurring operating losses and negative operating cash flow; it says available funds are insufficient for at least twelve months from the financial statements’ issuance. Its ability to raise funds through its share-sale program is tied to continued Nasdaq listing, which was under review after a delisting determination.
- 3Nexalin depends on outside manufacturers and clinical research organizations. Delays, quality problems or failures to meet regulatory requirements could disrupt device production or clinical studies.
Pełne sprawozdania finansowe →
O spółce Nexalin Technology, Inc.
Nexalin develops devices that use electrical signals delivered through electrodes on the head to stimulate the brain. Its SYNC device is intended for clinical use, while its HALO headset is being studied for physician-supervised home use; a clinical trial for insomnia is underway. Nexalin also develops software for doctors to oversee patients remotely, manage care and collect clinical information.
- Siedziba
- Houston, Texas
- Rok założenia
- 2010
- Notowana na
- Nasdaq Capital Market
- Koniec roku obrotowego
- December 31
Zbudowane z własnych raportów spółki Nexalin Technology, Inc. składanych do amerykańskiej Komisji Papierów Wartościowych i Giełd (SEC). Liczby są takie, jak zaraportowano, a historia na akcję przeliczona na dzisiejszą bazę akcji. To opisuje firmę — nie jest poradą inwestycyjną ani rekomendacją kupna lub sprzedaży.
